Please use this identifier to cite or link to this item:
Title: How bilastine is used to treat allergic rhinitis and urticaria in children
Filiation: Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Issue Date: Jan-2022
Publisher: Future Medicine Ltd
Citation: Immunotherapy.2022 01;(14)1:77-89
Abstract: Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2-<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.
PMID: 34850647
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. Infantil U. Niño Jesús > Artículos

Files in This Item:
File Description SizeFormat 
Rodriguez Del Rio_2021_How bilastine is used.pdfRodriguez Del Rio_2021_How bilastine is used105.26 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.